Las Vegas, NV -- (SBWIRE) -- 12/31/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks:Coronado Biosciences Inc(NASDAQ:CNDO),Plug Power Inc(NASDAQ:PLUG),Banro Corporation (USA)(NYSEMKT:BAA),Neuralstem, Inc.(NYSEMKT:CUR)
Coronado Biosciences Inc(NASDAQ:CNDO)managed to keep its loss at -5.09% on below-normal volume of 2.22Mshares. The stock settled at $2.61, after floating in a range of $2.58 - 2.90. Its latest price has reached market capitalization of $88.59M. Its 52-week range has been $1.25 - 12.70. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic.
How Should Investors Trade CNDO Now?Don’t Miss out a Special Trend Analysis
Plug Power Inc(NASDAQ:PLUG)trading on a volume of 2.21Mshares, higher than its standard daily volume. Shares have been closed at $1.63. Over the last twelve months, the stock has gained226% and faced a worst price of $0.12.Plug Power Inc. (Plug Power), is a provider of alternative energy technology focused on the design, development, commercialization and manufacture of fuel cell systems for the industrial off-road (forklift or material handling) market. The Company is focused on proton exchange membrane( PEM).
Is PLUG a Solid Investment at These Levels?Read This Report for Details
Banro Corporation (USA)(NYSEMKT:BAA)is up at $0.553 on above- normal volume of 2.15M shares during the last trading day. The stock has its 12-month range $0.41 - 3.15. Its Intraday range is $0.50 - 0.56.Banro Corporation (Banro) is a Canada-based gold exploration company.
How Should Investors Trade BAA Now?Don’t Miss out a Special Trend Analysis
In the last trading day, Neuralstem, Inc.(NYSEMKT:CUR)is on high volume, trading at a volume of versus its average daily volume ratio 2.14M/699,515.00 shares. At $2.94, the stock has attained market capitalization of 210.65MNeuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.
Will Investors Buy CUR After Reading This News?Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)